Get the Stockscreener App
3.77
0.27%
0.01
Neuphoria Therapeutics Inc stock is traded at $3.77, with a volume of 21,889.
It is up +0.27% in the last 24 hours and down -3.08% over the past month.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
See More
Previous Close:
$3.76
Open:
$3.74
24h Volume:
21,889
Relative Volume:
0.11
Market Cap:
$20.38M
Revenue:
$15.00M
Net Income/Loss:
$2.71M
P/E Ratio:
2.9627
EPS:
1.2725
Net Cash Flow:
$-2.89M
1W Performance:
+0.27%
1M Performance:
-3.08%
6M Performance:
-18.75%
1Y Performance:
-68.37%
1-Day Range:
$3.73
$3.78
1-Week Range:
$3.71
$3.84
52-Week Range:
$3.19
$21.40
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Name
Neuphoria Therapeutics Inc
Sector
Industry
Phone
781-439-5551
Address
100 SUMMIT DR, BURLINGTON
Compare NEUP vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
3.77 | 21.35M | 15.00M | 2.71M | -2.89M | 1.2725 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-28-23 | Reiterated | Maxim Group | Buy |
| Jan-10-22 | Initiated | Berenberg | Buy |
| Jan-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-22 | Initiated | Evercore ISI | Outperform |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
View All
Neuphoria Therapeutics Inc Stock (NEUP) Latest News
ACTU Stock Price and Chart — NASDAQ:ACTU - TradingView
Neuphoria Therapeutics Inc (NEUP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NEUP Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers 90.9% EPS SurpriseGeographic Revenue Trends - Vinanet
Neuphoria Therapeutics (NEUP) Pulls Back to $3.82 as Traders Eye Key Support ZoneVanna Flow - dars.gov.et
Neuphoria Therapeutics (NEUP) Pulls Back 1.27% to $3.9, Holds Above Key SupportKeltner Channel - dars.gov.et
Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders? - tradingview.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Neuphoria Therapeutics (NEUP) Slips to $3.88 as Bulls Defend Key SupportSector ETF Flow - dars.gov.et
NEUP Q2 2026 Earnings: Narrower-Than-Expected Loss Signals Lean Cost ManagementEarnings Decline Risk - dars.gov.et
NEUP Q2 2026 Earnings: Narrower-than-Expected Loss Delivers 90.9% EPS Surprise Amid Stock PullbackEarnings Weakness Phase - Vinanet
Scancell merges with Nasdaq shell Neuphoria to fund USD 89m Phase III melanoma trial - allsci.com
Neuphoria Therapeutics (NEUP) Holds Near $3.93 as Biotech Stock Tests Key Technical LevelsStock Analysis - vinanet.vn
Neuphoria Therapeutics (NEUP) Gains 3.55% as Stock Tests Key Resistance Near $4.14Chandelier Stop - dars.gov.et
Advising Nasdaq-listed Neuphoria Therapeutics Inc. On Its USD250M Merger With AIM-listed Scancell Holdings - Mondaq
Neuphoria Therapeutics Inc. (NEUP) Q2 2026 Earnings: Loss Narrows Sharply, Exceeding ExpectationsEPS Growth Report - dars.gov.et
Advising Nasdaq-listed Neuphoria Therapeutics Inc. on its USD250M merger with AIM-listed Scancell Holdings - Winston Taylor
Halper Sadeh LLC is Investigating Whether SAFT, NEUP, NRIM are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Neuphoria Therapeutics Inc (NEUP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neuphoria Therapeutics Inc (NASDAQ: NEUP) Share Price, NEUP Stock News, NEUP Share Price & Updates - Kalkine
NEUP|Neuphoria Therapeutics Inc|Price:3.970|Chg%:+0.330 - TradingKey
Neuphoria Therapeutics Inc (NEUP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neuphoria Therapeutics Inc (NEUP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neuphoria Therapeutics Inc (NEUP) Income Statement - tradingkey.com
Neuphoria Therapeutics (NEUP) Drops 7%: Key Levels in Focus After Sharp DeclineFibonacci Time Zone - po-news-eg.net
Neuphoria Therapeutics Inc. Revenue Breakdown – NASDAQ:NEUP - TradingView
NEUP|Neuphoria Therapeutics Inc|Price:3.810|Chg%:+0.170 - TradingKey
Neuphoria Therapeutics Inc (NEUP) Cash Flow - TradingKey
Neuphoria Therapeutics Market Sentiment - Benzinga España
NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
Monteverde & Associates investigates Neuphoria Therapeutics merger fairness for shareholders. - Pluang
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP) - PR Newswire
Neuphoria Therapeutics (NEUP) Proxy filing Summary - Quartr
Neuphoria Therapeutics to Merge with Scancell Holdings - TipRanks
Neuphoria Therapeutics (Nasdaq: NEUP) to be acquired by Scancell - Stock Titan
Neuphoria Therapeutics to Merge With Scancell; Holders to Receive ADSs Plus CVRs - TradingView
Scancell and Neuphoria agree all-share merger supported by up to US$89 million financing - Yahoo Finance UK
NEUPHORIA THERAPEUTICSSCANCELL EXPECTS TO SECURE UP TO $89 MLN IN FINANCING - Moomoo
Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell - Moomoo
Scancell Holdings plc agreed to acquire Neuphoria Therapeutics Inc. for $34.7 million. - marketscreener.com
Scancell, Neuphoria Therapeutics Agree All-share Merger - Moomoo
Scancell merges with Neuphoria after Merck axes trial; AstraZeneca breast cancer drug approved in EU - Endpoints News
Scancell agrees to buy Neuphoria, combined firm set to list on Nasdaq - marketscreener.com
Scancell And Neuphoria Therapeutics Announce Merger Agreement - TradingView
Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing - The Manila Times
Scancell And Neuphoria Therapeutics Announce Merger Agreement And Financing - TradingView
Scancell to join Nasdaq through Neuphoria merger and $89 million funding package - Proactive financial news
Scancell Holdings Secures £9 Million via UK Share Placing Ahead of Nasdaq Merger with Neuphoria Therapeutics - Kalkine Media
MRK, NEUP stocks drop as Merck scraps another Alzheimer’s drug trial under Neuphoria partnership - MSN
Price to book forward of Neuphoria Therapeutics Inc. – NASDAQ:NEUP - TradingView
Enterprise value to revenue forward of Neuphoria Therapeutics Inc. – NASDAQ:NEUP - TradingView
Neuphoria Therapeutics Inc Stock (NEUP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):